The Technical Analyst
Lineage Cell Therapeutics [LCTX]
Exchange: AMEX Sector: Healthcare Industry: Biotechnology
Lineage Cell Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.85% $1.170
America/New_York / 10 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 220.89 mill |
| EPS: | -0.120 |
| P/E: | -9.75 |
| Earnings Date: | Aug 08, 2024 |
| SharesOutstanding: | 188.80 mill |
| Avg Daily Volume: | 0.957 mill |
| RATING 2024-05-10 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.75 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -9.75 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.053 - 1.287 ( +/- 10.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-07 | Culley Brian M | Buy | 1 900 000 | Employee Stock Option (Right to Buy) |
| 2024-03-07 | Samuel George A. Iii | Buy | 650 000 | Employee Stock Option (Right to Buy) |
| 2024-03-07 | Howe Jill Ann | Buy | 650 000 | Employee Stock Option (Right to Buy) |
| 2024-02-11 | Samuel George A. Iii | Sell | 6 076 | Restricted Stock Units |
| 2024-02-11 | Samuel George A. Iii | Buy | 6 076 | Common Shares, no par value |
| INSIDER POWER |
|---|
| 98.21 |
| Last 93 transactions |
| Buy: 20 710 358 | Sell: 1 476 683 |
Forecast:
16:00 - $1.180
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.180
Forecast 2: 16:00 - $1.180
Forecast 3: 16:00 - $1.180
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.170 (-0.85% ) |
| Volume | 0.566 mill |
| Avg. Vol. | 0.957 mill |
| % of Avg. Vol | 59.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LCTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Latest Press Releases
2024-05-02 08:00:00 - Press Release
Lineage Cell Therapeutics To Report First Quarter 2024 Financial Results And Provide Business Update On May 9, 2024
Carlsbad, calif.--(business wire)---- $lctx #lineagecelltherapeutics--lineage cell therapeutics, inc. (nyse american and tase: lctx), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on thursday, may 9, 2024, following the close of the u.s. financial markets. lineage management will also host a conference call and webcast on thursday, may 9, 2024, at 4:30 p.m. eastern time/1:30 p.m. pacif.
2024-04-29 16:30:00 - Press Release
Lineage Announces Changes To Board Of Directors
Carlsbad, calif.--(business wire)---- $lctx #lineagecelltherapeutics--lineage cell therapeutics, inc. (nyse american and tase: lctx) is saddened to report the passing of its long-serving chairman of the board of directors, mr. alfred d. kingsley, and offers its deepest condolences to mr. kingsley's family for their loss. mr. kingsley served as chairman of the company's board of directors since july 2009, and was a significant contributor in the evolution of the company into a clinical-stage biotechnology company developing allog.
2024-03-18 08:00:00 - Press Release
Lineage Cell Therapeutics And The Christopher & Dana Reeve Foundation Proudly Announce The 2nd Annual Spinal Cord Injury Investor Symposium
Carlsbad, calif.--(business wire)---- $lctx #lineagecelltherapeutics--lineage cell therapeutics, inc. (nyse american and tase: lctx), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the christopher & dana reeve foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to again collaborate to present the 2nd annual spinal cord injury investor symposium ("2nd sciis"). th.
2024-03-13 08:00:00 - Press Release
Rg6501 (opregen®) Phase 1/2a Clinical Study 24 Month Results To Be Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
Carlsbad, calif.--(business wire)---- $lctx #lineagecelltherapeutics--lineage cell therapeutics, inc. (nyse american and tase: lctx), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a phase 1/2a clinical study (clinicaltrials.gov identifier: nct02286089) of rg6501 (opregen) in patients with geographic atrophy (ga) secondary to age-related macular degeneration (amd), will be presented at the 2024 retinal cell &.
2024-03-11 08:00:00 - Press Release
Rg6501 (opregen®) Preclinical Engraftment Results To Be Presented At 2024 Association For Research In Vision And Ophthalmology Meeting
Carlsbad, calif.--(business wire)---- $lctx #lineagecelltherapeutics--lineage cell therapeutics, inc. (nyse american and tase: lctx), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of rg6501 (opregen) will be presented at the 2024 association for research in vision and ophthalmology annual meeting (2024 arvo). the meeting will be held may 5-9, 2024, in sea.
Latest News
2024-05-10 00:33:02 - Seeking Alpha
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Ioana Hone - Head, Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Conference Call Participants Jack Allen - Baird William Wood - B. Riley Joe Pantginis - H.C.
2024-03-07 22:22:17 - Seeking Alpha
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - CFO Conference Call Participants Joe Pantginis - H.C Wainwright Jack Allen - Baird Kristen Kluska - Cantor Fitzgerald Mayank Mamtani - B. Riley Sean McCutcheon - Raymond James Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call.
2023-11-11 16:02:32 - InvestorPlace
3 Penny Stocks to Buy for the Next Bull Run
By corporate protocol and just plain old common sense, when it comes to penny stocks to buy, your first instinct should be this: don't. Yeah, I know that's not exactly a sexy opener for the topic at hand.
2023-11-09 23:37:06 - Seeking Alpha
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2023 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:12 PM ET Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q3 2023 Earnings Conference Call November 09, 2023, 16:30 PM ET Company Participants Brian Culley - CEO Jill Howe - CFO Gary Hogge - SVP, Clinical and Medical Affairs Ioana Hone - Head, IR Conference Call Participants Joseph Pantginis - H.C. Wainwright Abigail Gray - Baird Kristen Kluska - Cantor Fitzgerald Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call.
2023-10-17 17:14:14 - InvestorPlace
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.
2023-10-04 09:38:04 - Seeking Alpha
A Second Look At Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for degenerative diseases. The shares trade for just over a buck apiece. Five analyst firms have reissued Buy/Outperform ratings on the stock, with price targets ranging from $4.00 to $7.00 a share. The company is partnered with Genentech around its main developmental program and that is targeting a large potential market.
2023-08-10 18:16:09 - Zacks Investment Research
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.04 per share a year ago.
2023-05-11 22:29:02 - Seeking Alpha
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2023 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gary Hogge - Senior Vice President of Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird Joe Joe Pantginis - H. C. Wainwright Kristen Kluska - Cantor William Wood - B.
2023-04-10 19:57:17 - InvestorPlace
3 Penny Stocks to Buy During Market Downturns
Penny stocks to buy have been the talk of the town in recent weeks as cyclical assets have started to make a comeback this year. Penny stocks tend to perform poorly during market downturns.
2023-03-09 23:19:05 - Seeking Alpha
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2022 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - Chief Financial Officer Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird William Wood - B. Riley Securities Kristen Kluska - Cantor Fitzgerald Joe Pantginis - HC Wainwright Joanne Lee - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Conference Call.